PharmClass

MAFTislelizumab (Tevimbra) Concentrate For Solution For Infusion 100 mg/10 mL

1) Tislelizumab in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have PD-L1 expression on ≥50% of tumour cells, with no EGFR or ALK genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
2) Tislelizumab in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). Patients with locally advanced squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
3) Treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic NSCLC.
4) Tislelizumab in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma.
5) Treatment of patients with unresectable, recurrent, locally advanced, or metastatic oesophageal squamous cell carcinoma after prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable, recurrent, locally advanced, or metastatic setting.
6) Tislelizumab in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.

MSHLTislelizumab Concentrate For Solution For Infusion 100 mg/10 mL

1) Tislelizumab in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have PD-L1 expression on ≥50% of tumour cells, with no EGFR or ALK genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
2) Tislelizumab in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). Patients with locally advanced squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
3) Treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic NSCLC.
4) Treatment of patients with unresectable, recurrent, locally advanced, or metastatic oesophageal squamous cell carcinoma after prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable, recurrent, locally advanced, or metastatic setting.
5) Tislelizumab in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma.
6) Tislelizumab in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.